InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE
Summary
BEIJING, April 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer a...
Description
BEIJING, April 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer a...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source